<DOC>
	<DOCNO>NCT00901849</DOCNO>
	<brief_summary>This study evaluate feasibility combine two drug , Tarceva ( anti-EGFR agent ) , Rapamycin ( mTOR inhibitor ) , child progressive low-grade glioma fail initial conventional treatment . In addition evaluate toxicity drug regimen , potential efficacy regimen assess .</brief_summary>
	<brief_title>Tarceva/Rapamycin Children With Low-grade Gliomas With Without Neurofibromatosis Type 1 ( NF1 )</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>child le 21 year age , without neurofibromatosis , recurrent lowgrade glioma . patient without NF1 must fail form conventional therapy , radiotherapy , chemotherapy ( carboplatin/vincristine ) eligible , include treat wtih initial surgery . Patients receive radiotherapy eligible . child type histologically prove lowgrade glioma eligible ; reoperation time recurrence mandatory entry study . patient intrinsic brain lesion , believe neuroradiographically consistent lowgrade glial tumor , neurofibromatosis type 1 treat without histological confirmation . patient without neurofibromatosis type 1 must histological confirmation lowgrade glial tumor prior entry study . patient must Karnofsky score great equal 50 % child great 10 year age , Lansky score great equal 50 % patient le 10 year age . patient unable walk paralysis , able use wheelchair , consider ambulatory purpose assess performance score . patient must life expectancy least 12 week . patient must able swallow medication tablet form . patient must adequate organ function , include : peripheral ANC great 1,000/microliters ; platelet count great 100,000/microliters ; hemoglobin great 8 gm , dl ( pRBC transfusion allow maintain hemoglobin &gt; 8 g/dl ) patient must adequate renal function , define normal serum creatinine age patient must adequate liver function , define total bilirubin le 1.5 time upper limit normal age , SGPT ( ALT ) less 2.5 time upper limit normal age patient must MR scan within 3 week start treatment patient , and/or parent legal guardian , must sign recent informed consent institutional , FDA , NCI requirement human study must meet . patient must active tumor . pregnancy breast feed exclusion criterion , potential mutagenicity cytotoxicity drug develop fetus unknown . A pregnancy test must obtain female postmenarchal . Males female reproductive potential may participate unless agree use effective contraceptive method . patient uncontrolled infection exclude . patient previously receive Tarceva Rapamycin exclude . patient antiepileptic and/or corticosteroid allow study long stable wean dose 7 day prior study initiation ( define first day treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>